HR+/HER2- Therapies Take The Stage: With ASCO 2018 now behind us, we have time to reflect on the advances and challenges that remain for patients with metastatic breast cancer (mBCa). Hormone receptor positive (HR+) (mBCa) was a key focus area for this year’s meeting. Key takeaways and analysis of selected HR+ mBCa data are presented in this blog post.
Context’s mission is to develop important drugs to treat hormonally-driven cancers. Any drug can be differentiated, but an important drug exhibits the attributes required to directly address unmet needs for patients. Until lately, there has been a dearth of important antihormonal drugs in development.